71 results about "Renal interstitial fibrosis" patented technology

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

A composition for repressing transformation growth factor β contains theanine as an active substance. The composition is useful for preventing or treating chronic glomerulonephritis, renal interstitial fibrosis, hepatic fibrosis, hepatic cirrhosis, idiopathic interstitial pneumonia, keloid, hidebound disease, arterial sclerosis, myocardial infarction, cardiac fibrosis, restenosis, acute megakaryoblastic leukemia, adult T-cell leukemia, chronic fatigue syndrome or ordinary fatigue.

The invention provides a single-composition traditional Chinese medicine preparation, and a preparation method and application thereof. The traditional Chinese medicine preparation is characterized by being prepared from a main raw material of an artificially cultivated cicada active component. The single-composition traditional Chinese medicine preparation provided by the invention has obvious treatment and prevention effects on generation and development of chronic renal failure. According to animal experiments, the single-composition traditional Chinese medicine preparation provided by the invention can improve kidney functions, lower serum creatinine level and urea nitrogen level, increase hemoglobin, reduce ECM (extracellular matrix) deposition, mitigate renal tubulointerstitial injury and delay renal interstitial fibrosis; besides the single composition is safe, effective and without obvious toxic or side effects.

The invention belongs to the technical field of a biological preparation, and discloses a novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome and a preparation method. The novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome has main component of cup-shaped membrane-shaped vesicles which are prepared through combination of intracellular multivesicular bodies with cell membranes, are secreted outside cells and are about 100nm in size. The preparation method of the novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome comprises an ultracentrifugation method, a chemical reagent precipitation method, an ultrafiltration and centrifugation method and a magnetic bead immunization method. When the MSC cell exosome is extracted and used for treatment of an animal model suffering from diabetic nephropathy, the inventor finds that MSC-Ex has the treatment effects of restraining YAP activity, allevaiting renal interstitial fibrosis and delaying diabetic nephropathy.

The invention provides a screening method for proteinuria component induced renal interstitial fibrosis based on a micro-fluidic chip. The micro-fluidic chip comprises twelve identical structure units. The structure units are connected through central pools. Each structure unit is composed of a stimulant inlet pool (1), a fluid buffer channel (2), a cell culture pool (3) and a central pool (4). The screening method for the proteinuria component induced renal interstitial fibrosis based on the micro-fluidic chip integrates chip cell culture, cell and factor interaction, fluid stimulation, cell marking and cell responding signal detection on the chip of several square centimeters, and can be used for analyzing a proteinuria component induced renal interstitial fibrosis mechanism. Compared with a perforated plate technology, the screening method for the proteinuria component induced renal interstitial fibrosis based on the micro-fluidic chip saves the cumbersome step of repeated cell inoculation, solves the problems that different factors cannot act on cells at the same time under the flow condition, reduces the consumption of the cells and reagent, and can achieve a plurality of experiment parameters through one-time operation.

The invention relates to a beta-carboline compound and a synthetic method and application thereof, and belongs to the technical field of medicine. The structure of the compound is shown as the formula I (the formula I is shown in the specification). After an initial test, it is indicated that the in-vitro anti-renal-fibrosis activity of the compound is remarkable, the treatment effect on renal interstitial fibrosis caused by obstruction of the left ureter of a Balb / c mouse is good, the good potential medical value is achieved, and the beta-carboline compound and the synthetic method and application thereof can be used for preparing various kinds of anti-renal-fibrosis and anti-chronic-kidney-disease medicine.

The invention provides an application of a Aspidopterys obcordata Hemsl. extract in preparation of a medicine for preventing and / or treating diabetic nephropathy. The medicine for preventing and / or treating diabetic nephropathy provided by the invention takes the Aspidopterys obcordata Hemsl. extract as an active component, and the medicine can be prepared into any dosage form together with pharmaceutically common auxiliary materials. The Aspidopterys obcordata Hemsl. extract can relieve kidney injury and inhibit proliferation of fibroblasts at a high glucose level, has the effect of resisting renal interstitial fibrosis, has no obvious cytotoxicity to normal tissue cells, and has good application prospect in treatment of diabetic nephropathy.

The invention relates to the field of purposes of extracts of traditional Chinese medicine, in particular to application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis. Lignans accounts for 30-90% of the total weight of the eucommia ulmoides lignans extracts, and the effective constituent of pinoresinol diglucoside in the lignans accounts for 1%-15% of the total weight of the eucommia ulmoides lignans extracts.

The invention discloses an application of KD025 in preparation of drugs for preventing and treating chronic renal fibrosis, and especially relates to an application of KD025 in preparation of drugs for resistance of inflammation and protection of renal tubular epithelial cells. KD025 can alleviate the pathological changes of a mice model with chronic renal interstitial fibrosis, reduce the expression level of fibrosis factors in mice kidney tissues, reduce inflammatory reaction of kidney tissues and macrophages, protect the renal tubular epithelial cells in the fibrosis model and reverse transdifferentiation.

The invention discloses a determination method of the potency of a traditional Chinese medicine zedoary turmeric oil by using metabolomics. The method comprises the steps that: an unilateral ureteral obstruction induced renal interstitial fibrosis model is adopted, an animal modeling is carried out; processing and sampling are carried out after animal modeling is carried out for 3 days, 7 days, 14 days, 21 days, and 28 days; animal kidney tissues are fetched; kidney tissue pathological changes are observed by using an optical microscope; serum samples are prepared, and 1H NMR spectral data is obtained; NMR data processing and pattern recognition analysis are carried out; and analysis is carried out by using SPSS13.0 software. According to the invention, information of large amount of endogenous metabolites in bodies can be obtained with the metabolomic technology, and metabolite changes of potencies of various effective components in zedoary turmeric oil upon various targets can be screened. Therefore, the potency of zedoary turmeric oil can be comprehensively evaluated. The invention provides an excellent method for evaluating zedoary turmeric oil potency.

The invention relates to an establishment method for a pig unilateral ureter obstruction recanalization model, and belongs to an establishment method for animal models. A Bama minature pig is selected, combined anesthesia is adopted, a polyethylene piece is curled into a polyethylene pipe to be wound around a kidney ureter, and the two ends of the ureter are ligatured through the number 10 surgery sutures so that the right side ureter can be completely obstructed. The method has the advantage that the pig unilateral ureter obstruction recanalization model is successfully established, a good experimental platform is provided for the research on renal interstitial fibrosis, and meanwhile a good tool is provided for medicine experiments through the model; through the analysis on serum markers and pathology of all time points of obstruction and recanalization, the changes, of different degrees, happening to a kidney on the aspects of general pathology and physiological functions when obstruction recanalization is achieved at different time points can be easily found.

The invention discloses a research method for the pharmacologic action of mangiferin on mouse diabetes. The research method comprises material selection and an experimental method, biochemical parameter evaluation, histological analysis, measurement of reactive oxygen species (ROS), determination of malondialdehyde (MDA) and antioxidase, analysis of renal tissue inflammatory factors, immunofluorescent staining, Western blotting and statistic analysis. According to the research method, a trichrome staining method is utilized to observe renal morphology; a kit is utilized to determine a blood biochemical index; levels of inflammatory cytokines, the antioxidase, the MDA and the ROS are determined; expression of fibronectin, collagen I and alpha-SMA is detected by an immunohistochemical method, and regulation of paths of TGF-beta 1 and phosphatase and tensin homolog / phosphatidylinositol 3-hydroxy kinase / protein kinase B (PTEN / PI3K / Akt) is detected by Western blotting; researches show thatthe mangiferin can significantly improve the renal dysfunction of diabetic mice; renal interstitial fibrosis can be prevented by reducing positive expression of fibronectin (FN), collagen type I (ColI) and alpha-smooth muscle actin (SMA) during therapy with the mangiferin; and meanwhile, mangiferin increases the antioxidase, reduces phosphorylation of the PI3K and Akt, inhibits the renal interstitial fibrosis, and provides more theoretical foundations for clinical application of traditional Chinese medicine in treating diabetes.

The invention relates to application of fisetin in preparation of a medicine for preventing and treating uric acid nephropathy, and belongs to the field of medicine. The invention provides application of fisetin or salt thereof in preparation of the medicine for treating and / or preventing the uric acid nephropathy. Animal experiments prove that the fisetin can regulate protein expression of kidney urate transporters URAT1, OAT1, OAT3 and ABCG2, improve uric acid excretion rate and obviously reduce serum creatinine, blood urea nitrogen and blood uric acid levels, also has an effect of inhibiting renal interstitial fibrosis, can obviously reduce expression quantities of fibrosis-related proteins such as alpha-SMA, cologen I and fibronectin, has an exact prevention / treatment effect on the uric acid nephropathy and provides a new choice for clinical medication.

The invention relates to a composition for preventing and / or treating a chronic kidney disease. The composition for preventing and / or treating the chronic kidney disease is prepared from the followingcomponents in parts by weight: icariin, rheum emodin, ferulic acid and ligustrazine, wherein the ratio of the icariin to the rheum emodin to the ferulic acid to the ligustrazine is 1.3 to 1.2 to 1.3to 1. An experiment result shows that the composition interferes with signaling pathway activation of a fibrosis promoting central event TGF-beta / Smad / EZH2 by restraining Smad3 phosphorylation and EZH2 activity, and renal interstitial fibrosis is resisted. By protecting renal innate cells, a hypoxia-inducible factor HIF-2alpha is stabilized, synthesis of endogenous EPO is increased, an iron metabolism disorder caused by high expression of Hepcidin-25 is antagonized, renal anemia is improved, and a renal failure is delayed. The invention further relates to application of the composition to preparation of drugs for preventing and / or treating the chronic kidney disease. The composition for preventing and / or treating the chronic kidney disease has the advantages that a preparation method is simple and convenient, the components work collaboratively, the therapeutic effect is good, and good application prospects are achieved.

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

The invention relates to the field of applications of traditional Chinese medicine extracts and in particular provides an application of aucubin to preparation of medicines for treating renal interstitial fibrosis. Aucubin is preferably the eucommia ulmoides samara extract, wherein the purity of aucubin is above 98%.

The invention discloses application of NSC228155 in treating chronic renal interstitial fibrosis, and particularly relates to application of the NSC228155 in treating the chronic renal interstitial fibrosis by resisting inflammation and protecting renal tubular epithelial cells (RTECs). The NSC228155 can relieve pathological change of a chronic renal interstitial fibrosis mouse model, reduce the expression level of fibrosis factors of renal tissue of a mouse, reduce inflammatory reaction of renal tissue and fibroblasts, protect the RTECs in the fibrosis model and reverse the transdifferentiation effect of the RTECs.

The invention relates to use of pterostilbene in preparing a medicine for preventing and treating high uric acid nephropathy, and belongs to the field of medicine, and provides use of the pterostilbene or a pharmaceutically acceptable salt thereof in preparing the medicine for treating and / or preventing the high uric acid nephropathy. Experimental results show that the pterostilbene can significantly reduce the level of serum uric acid, inhibits renal interstitial fibrosis, can significantly reduce the expression of fibrosis-related proteins such as alpha-SMA, collagenI, collagenIV and fibronectin, has a definite therapeutic effect on the high uric acid nephropathy, and provides a new option for clinical medication.

The invention discloses applications of gene modified mesenchymal stem cell derived microvesicles in preparation of drugs for treating renal injury. Applications of mesenchymal stem cell derived and gene modified miR-34a-MSC-MV, which are specifically designed microvesicles, in preparation of drugs for treating renal injury are included. The level of miR-34a is detected by inducing the overexpression of the miR-34a in MSCs through lentiviral vectors. Through the discovery from pathological observation, the damage level of renal tissue can be obviously improved, renal interstitial fibrosis, lymphocyte infiltration and swelling and necrosis degrees of renal tubules can be obviously alleviated, and renal histopathological scores can be significantly reduced. Through in vivo and in vitro experiments, repair effects of MV and miR-34a-MV are verified; the effects of gene modified stem cells and paracrine products thereof are cleared; and an action mechanism is preliminarily discussed.

The invention discloses a cordyceps cicadae polysaccharide, a preparation method and application thereof in preparation of a medicament for preventing renal interstitial fibrosis. The method comprisesthe following steps: pulverizing cordyceps cicadae fruiting bodies, and performing sieving to obtain cordyceps cicadae fruiting body powder; ultrasonically extracting the fruiting body powder with distilled water, and then carrying out ultrahigh pressure treatment; preparing crude polysaccharide of the cordyceps cicadae fruiting body after the treatment; and then performing separation by using DEAE-cellulose anion column chromatography, and performing freeze-drying to obtain the purified polysaccharide. The method successfully prepares the cicada cordyceps polysaccharide treated and modifiedby ultrahigh pressure, and has the advantages of simple steps and higher efficiency. The intervention on a rat glomerular epithelial cell model shows that the polysaccharide can effectively inhibit the proliferation of rat glomerular epithelial cells (HMC), and has wide application prospect in the aspect of preventing renal interstitial fibrosis. The oxidation resistance of the cordyceps cicadae polysaccharide is obviously improved, and the cordyceps cicadae polysaccharide induces the apoptosis of high-glucose rat glomerular mesangial cells, has no toxicity to normal cells, and has good research value and commercial value.

The invention discloses an application of panax japonicus saponin IVa in preparation of drug for treating nephritis or renal fibrosis drug. The panax japonicus saponin IVa is extractive of Aralia taibaiensis; study of an inventor finds that the panax japonicus saponin IVa has liver protection effect. The extracting method of the panax japonicus saponin IVa is simple, and the panax japonicus saponin IVa can inhibit expressions of MCP-1, TNF-alpha, 1L-6 inflammatory factors of NRK-49F cells induced by TGF-beta 1, reduce the renal interstitial fibrosis of UUO mice, and treat nephritis or renal fibrosis caused by various reasons; the effect is significant.

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate and thiotungstate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate wherein exemplary thiotungstates include mono-, di-, tri-. And tetrathiotungstate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

The invention relates to ethanol extracting solution of desmodium renifolium and an application thereof and belongs to the field of medicines. The ethanol extracting solution has the beneficial effects that the desmodium renifolium as a Dai medicine has an effect of preventing and treating chronic renal failure, and the mechanism is associated with improvement of renal anemia of a rat with chronicrenal failure and reduction of renal injury and renal interstitial fibrosis degree. The invention provides an application direction of the desmodium renifolium, the ethanol extracting solution and water extracting solution thereof in preventing and treating the chronic renal failure, provides a preparation method of desmodium renifolium tablets and provides pharmacodynamic basis for further research and development of the desmodium renifolium tablets.

The present invention provides a single-traditional Chinese medicine preparation and a preparation method and an application thereof. The single-traditional Chinese medicine preparation is prepared byusing active ingredients of artificially cultivated cordyceps sobolifera as a main raw material. The provided single-traditional Chinese medicine preparation has obvious therapeutic and preventive effects on occurrence and development of chronic renal failure. Animal experiments show that the provided single-traditional Chinese medicine preparation can improve renal functions, reduce serum creatinine and urea nitrogen levels, increase hemoglobin, reduce deposition of ECM, reduce renal tubulointerstitial damages, and delay renal interstitial fibrosis. The single-traditional Chinese medicine preparation is safe, effective and free of obvious toxic and side effects.

A Chinese medicine for treating chronic renal interstitial fibrosis and chronic renal insufficiency is prepared from 10 Chinese-medicinal materials including red sage root, astragalus root, Chinese angelica root, notoginseng, etc. Its preparing process is also disclosed.

The invention discloses application of a ferroptosis inhibitor Liproxstatin-1 in preparation of drugs for relieving renal fibrosis, and belongs to the technical field of biological medicines. The system of the invention clarifies the occurrence of iron deposition and the expression of ferroptosis-related proteins in a renal fiber model caused by unilateral ureteral ligation of mice; and meanwhile, the ferroptosis inhibitor Liproxstatin-1 is administered intraperitoneally, which proves that the Liproxstatin-1 can inhibit ferroptosis of renal tubular epithelial cells, thereby inhibiting the secretion of fibrosis-promoting factors TGF-beta1, CTGF and PDGF and the activation of myofibroblasts, finally reducing the degree of renal fibrosis of mice, and providing potential drugs and new ideas for the treatment of renal fibrosis.

The invention provides a composition for improving kidney dysfunction and belongs to the technical field of ginseng deep-processing. The composition comprises, by weight, 2-6 parts of ginsenoside Rg2,1-5 parts of ginsenoside Rg5 and 1-3 parts of ginsenoside Rk1. The composition participates in slowing down the progress of chronic kidney interstitial fibrosis by inhibiting HK-2 phenotypic differentiation so as to improve chronic kidney dysfunction. It is verified that the composition can remarkably improve kidney functions of patients at 2-3 stages of chronic kidney dysfunction CKD.

The invention belongs to the field of medicine and particularly relates to application of anisodine to preparation of drugs for preventing or treating renal fibrosis. The technical problem to be solved is to provide novel application of the anisodine, particularly application of the anisodine to preparation of the drugs for preventing or treating the renal fibrosis. Specifically, the anisodine has the efficacies of decreasing the level of Scr and BUN in serum and the level of alpha-SMA and TGF-beta protein in renal tissues and promoting or improving fibrous tissue proliferation in renal interstitium, which indicates that the anisodine is capable of protecting and improving renal interstitial fibrosis. The anisodine serving as an active ingredient is preferably selected from anisodine hydromide. Experiments prove that the anisodine hydromide is capable of preventing or treating the renal fibrosis and improving the renal fibrosis by inhibiting proliferation and activation of myofibroblasts in the renal tissues, and accordingly a novel selection for clinical prevention and treatment of the renal fibrosis is offered.

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.